ReviewCurrent oncology reports2022
Fatty Acid Metabolism and Cancer Immunotherapy.
Review in Current oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 50 citations in OpenAlex.
- ACSBG1‑driven lipid reprogramming unveiled: A fatty acid metabolism‑associated prognostic model for lung adenocarcinoma.Oncology reports · 2026Article
- Novel fatty acid metabolism-related molecular subtyping and prognostic signature for breast cancer.Translational cancer research · 2026Article
- PPIA regulates fatty acid and glutamine metabolism in lung adenocarcinoma based on multiomics prognostic model and experiment validation.Scientific reports · 2026Article
- Gene signatures of palmitoylation and fatty acid metabolism predict prognosis and immunotherapy response in breast cancer patients by machine learning, single-cell analysis, and experimental validation.Frontiers in pharmacology · 2026Article
- Metabolic reprogramming orchestrates an immunosuppressive microenvironment in anaplastic thyroid cancer: mechanisms and clinical perspectives.Frontiers in immunology · 2026Review
- Fatty acid metabolic signature reveals FASN as an immunosuppressive factor in DLBCL tumor microenvironment.Medical oncology (Northwood, London, England) · 2025Article
- The recurrence or metastasis related gene predicts the prognosis of extremity and trunk soft tissue sarcoma.Precision clinical medicine · 2025Article
- Potential mechanism of inhibitory effect of "medicine food homology" curcumin and its analogue EF24 on oral squamous cell carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Construction of lung adenocarcinoma subtype and prognosis model based on fatty acid metabolism-related genes.Discover oncology · 2025Article
- Development of a machine learning-based predictive risk model combining fatty acid metabolism and ferroptosis for immunotherapy response and prognosis in prostate cancer.Discover oncology · 2025Article
- Analysis of expression characteristics of ferroptosis-related lncRNAs in gastrointestinal cancer patients in Asia.Discover oncology · 2025Article
- Histone lactylation-driven B7-H3 expression promotes tumor immune evasion.Theranostics · 2025Article
- Robust machine-learning based prognostic index using fatty acid metabolism genes predicts prognosis and therapy responses in glioblastoma.Journal of Cancer · 2025Article
- Immune-metabolic crosstalk in HNSCC: mechanisms and therapeutic opportunities.Frontiers in oncology · 2025Review
- Fatty acid metabolism influences the immune microenvironment in papillary thyroid cancer and identifies SCD as a novel biomarker.Frontiers in endocrinology · 2025Article
- Article
- Obesity enhances the response to neoadjuvant anti-PD1 therapy in oral tongue squamous cell carcinoma.Cancer medicine · 2024Article
- Article
- SLC27A2 is a potential immune biomarker for hematological tumors and significantly regulates the cell cycle progression of diffuse large B-cell lymphoma.BMC medical genomics · 2024Article
- Development of fatty acid metabolism score based on gene signature for predicting prognosis and immunotherapy response in colon cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewIn this review, we update the latest findings on the impacts of FA metabolism reprogramming on the phenotypes and functions of immune cells in tumor-related immune responses. We also summarize the combinatorial interventions of FA metabolism, which improve the effects of current immunotherapies. RECENT
findingsMultiple studies have shown that either the abnormality in signaling pathways or nutrition competition in the TME can lead to phenotypic reprogramming of FA metabolism and functional changes in tumor-infiltrating immune cells, thereby influencing the therapeutic effects of cancer immunotherapies. Accordingly, regulating FA metabolism in immune cells has emerged and become promising approaches to synergize with immunotherapies. One of the mechanisms behind suboptimal therapeutic effects of immunotherapies is metabolic reprogramming of the TME that impairs immunosuppressive activity. FA metabolism is a crucial process involved in the survival and function of primary immune cells. It is of great significance to explore the feasibility of overcoming FA metabolic barriers to improve cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.